Individual specific variable drug response against similar drugs raises a significant
challenge for the effective and safe treatment of many human diseases. Pharmacogenomics …

Recent cancer pharmacogenomic studies profiled large panels of cell lines against
hundreds of approved drugs and experimental chemical compounds. The overarching goal …

The field of pharmacogenomics is an area of great potential for near-term human health
impacts from the big genomic data revolution. Pharmacogenomics research momentum is …

Objectives Pharmacogenomics (PGx) is often considered a low-hanging fruit for genomics–
electronic health record (EHR) integrations, and many have expressed the notion that drug …

The overall goal of translational oncology is to identify molecular alterations indicative of
cancer or of responsiveness to specific therapeutic regimens. While next-generation …

Aim: Six modern PGx assays were compared with the Pharmacogenomics Knowledge Base
(PharmGKB) to determine the proportion of the currently known PGx genotypes that are …

Objectives To determine the mechanism of action of valproic acid (VPA) in the adult central
nervous system (CNS) following traumatic brain injury (TBI) and hemorrhagic shock (HS) …

Background The regulatory effect of inherited or de novo genetic variants occurring in
promoters as well as in transcribed or even coding gene regions is gaining greater …

Nowadays, the personalized approach to health care and cancer care in particular is
becoming more and more popular and is taking an important place in the translational …

Epilepsy is the most common chronic neurologic disorder in the world, affecting 1-2% of the
population. Besides, 30% of epilepsy patients are drug-resistant. Genomic mutations seem …